Current clinical trials in melanoma using monoclonal antibodies.
Company
Antibody
Target
Function
Status
Antagonistic Abs.
Bristol-Myers Squibb
Ipilimumab (Yervoy)
CTLA-4
Relieve immune block
Approved
Bristol-Myers Squibb
MDX-11061
PD-1
Relieve immune block
Phase II (completed)
Curetech Ltd. (Israel)
CT-011
PD-1
Relieve immune block
Phase II (recruiting)
Merck
MK-3475
PD-1
Relieve immune block
Phase I (recruiting)
Bristol-Myers Squibb
MDX-1105-01
PD-L1
Relieve immune block
Phase I (recruiting)
Agonistic Abs.
Bristol-Myers Squibb
BMS-663513
4-1BB
Stimulate T cells
Phase II (completed)
Pfizer
CP870,8932
CD40
Stimulate T cells
Phase I (recruiting)
Tolerx
TRX518
GITR
Inhibit T regs
Phase I (on hold)
Portland Providence Medical Center
Anti-OX40
OX40
Stimulate T cells
Phase II (not open yet)
1Additional phase I studies are ongoing, in combination with Ipilimumab or with melanoma vaccines. 2Together with melanoma vaccine and an immune stimulant called Oncovir poly IC : LC (one phase I study) or with Tremelimumab (another phase I study).